A New Era in Therapy
Against Blindness
66% of blindness in Europe and the US is caused by retinal diseases - and thus preventable.
Our Mission
deepeye empowers the field of ophthalmology with AI-driven optimal therapy planning support, enabling additional insights into treatment data of patients suffering from retinal eye diseases. These conditions such as Age-related Macular Degeneration (AMD) are prevalent in over 12% of the European and US population, causing more than 66% of cases of blindness. Through our precision medicine platform, we aim to address the root causes of these vision impairments.
Our Partners
What Sets Us Apart
The Digital Therapy Assistant
At deepeye, we’re pioneering a shift in retinal therapy through our specialized AI tools for ophthalmology. Our innovation supports the therapy process, enabling doctors to make more informed decisions, thereby improving patient outcomes.
Highlights of AI 2nd opinion
Based on proven clinical method that led to 3x better outcomes and kept almost 2x more patients in vision-preserving treatment compared to state-of-the-art.
Focus on reducing therapy burden on clinicians and patients to improve treatment adherence.
Aims at boosting therapy effectiveness and efficiency in response to the growing prevalence of retinal diseases worldwide.
© 2021 Eye Center at St. Franziskus Hospital Münster
Ease of Adoption
Seamless Path to Advanced Ophthalmic Solutions
At deepeye, we've engineered our solution to ensure a seamless transition for doctors. Our integration with popular imaging software and collaboration with major OCT device manufacturers significantly lowers the barrier to entry, making the adoption of our innovative AI tools straightforward.
Highlights
1-click integration into existing eye imaging software, simplifying the transition to our platform.
First to launch a retinal treatment support tool with device-agnostic AI, now embedded in major OCT manufacturers' software for enhanced 3D eye scan data analysis.
Revolutionizing Clinical Studies with deepeye® Research
Discover the future of clinical studies with deepeye® Research, a cutting-edge AI platform transforming retinal therapy research. Our approach, honed through Europe's leading clinical methodologies, propels deepeye® to the forefront of innovation in anti-VEGF trials.
Highlights
AI-Enhanced Research: Our platform empowers study teams across pharmaceuticals, medical devices, and payors, offering unparalleled insights and efficiency.
Advanced Analysis Capabilities: From supporting Phase IV studies to extracting new insights from Phase II-III data, our technology enables deeper understanding of OCT scans.
Comprehensive Data Management: Our system expertly handles diverse datasets, producing anonymized, standardized data and insightful AI reports for a complete research solution.
deepeye® Research is more than just a tool. It is a partnership in advancing precision medicine, enhancing clinical research, and shaping the future of need-based retinal therapy.
